apocell Home Contact Us



Phase I Trials

Client: Confidential
Purpose: Pharmacodynamic Analysis of a Treatment for Chronic Kidney Disease
Endpoints: CEC enumeration; protein expression in CECs
Trial Sites: 4
Expected Patient Enrollment: 18



Phase II Trials

Client Name: Reata Pharmaceuticals
Purpose: Analysis of the Clinical Effects of a Novel Treatment for Moderate to Severe Chronic Kidney Disease
Biomarkers: iNOS expression in CECs
Trial Sites: 37
Expected Patient Enrollment: 100
Results: Pergola, PE, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3a-4 CKD.